Wedbush reaffirmed their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a $10.00 target price on the stock.
Separately, HC Wainwright reiterated a buy rating and set a $15.00 price objective on shares of TScan Therapeutics in a research note on Thursday, March 7th.
Get Our Latest Analysis on TCRX
TScan Therapeutics Price Performance
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.08. TScan Therapeutics had a negative net margin of 423.86% and a negative return on equity of 60.65%. The firm had revenue of $7.21 million during the quarter, compared to analysts’ expectations of $2.94 million. Equities analysts predict that TScan Therapeutics will post -1.03 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of TCRX. Pale Fire Capital SE acquired a new position in TScan Therapeutics during the 3rd quarter valued at approximately $42,000. Letko Brosseau & Associates Inc. acquired a new position in TScan Therapeutics during the 3rd quarter valued at approximately $83,000. Cannon Global Investment Management LLC acquired a new position in TScan Therapeutics during the 1st quarter valued at approximately $139,000. Finally, abrdn plc acquired a new position in TScan Therapeutics during the 4th quarter valued at approximately $1,166,000. Institutional investors own 82.83% of the company’s stock.
About TScan Therapeutics
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
See Also
- Five stocks we like better than TScan Therapeutics
- Why Invest in High-Yield Dividend Stocks?
- 3 Stocks Leading the U.S. Agriculture Comeback
- Best Stocks Under $10.00
- How to Use Put Debit Spreads to Profit From Falling Stocks
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.